The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects
Open accessAbstract
Higher rates of glucose usage generally correlate with poor prognosis in several types of malignant tumours. Experimental studies (both in vitro and in vivo) have shown that 2-deoxy-D-glucose (2-DG), a glucose analog and glycolytic inhibitor, enhances radiation-induced damage selectively in tumor cells while protecting normal cells, thereby suggesting that 2-DG can be used as a differential radiomodifier to improve the efficacy of radiotherapy. Clinical trials undertaken to study the feasibility, safety, and validity of this suggested approach will be described. Based on 2-DG-induced radiosensitization observed in primary organ cultures of cerebral glioma tissues, clinical trials were designed taking into consideration the radiobiology of gliomas and pharmacokinetics of 2-DG. Phase I/II clinical trials have unequivocally demonstrated that a combination of 2-DG (200-300 mg 2-DG per kg body weight orally administered after overnight fasting, 20 min before irradiation) with large weekly fractions (5 Gy/fraction) of low-LET radiotherapy is well tolerated without any acute toxicity or late radiation damage to the normal brain tissue. Nonserious transient side effects similar to hypoglycemia induced disturbances like restlessness, nausea, and vomiting were observed at the 2-DG doses used. Data from these trials involving more than 100 patients have clearly indicated a moderate increase in the survival, with a significant improvement in the quality of life with clinicopathological evidence of protection of normal brain tissue. A phase III multicentric trial to evaluate the efficacy of the combined treatment is in progress. Directions for future studies are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sympathetic control of hepatic glycogenolysis during glucopenia in man
Brodows, R. G., Pi-Sunyer, F. X., & Campbell, R. G. (1975) · Metabolism · doi:10.1016/0026-0495(75)90141-9 · Cited by 45
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., Williams, L. J., Wang, Z., Bristow, C. A., Carugo, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.024 · Cited by 611
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy
Zhang, D., Li, J., Wang, F., Hu, J., Wang, S., & Sun, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.003 · Cited by 462
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
Meijer, T. W. H., Kaanders, J. H. A. M., Span, P. N., & Bussink, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0858 · Cited by 433
Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship
Netea-Maier, R. T., Smit, J. W. A., & Netea, M. G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.037 · Cited by 326
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2478 · Cited by 266
Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death
Cheng, G., Zielonka, J., Dranka, B. P., McAllister, D., Mackinnon, A. C., Joseph, J., & Kalyanaraman, B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3928 · Cited by 263
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI
Nasrallah, F. A., Pagès, G., Kuchel, P. W., Golay, X., & Chuang, K.-H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.79 · Cited by 179
Yao, J., Chen, S., Mao, Z., Cadenas, E., & Brinton, R. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021788 · Cited by 169
“The safety profile of 2-DG has been investigated in multiple preclinical and clinical studies [52,53,54,55,56,57].”
BackgroundDeoxyglucose prevents neurodegeneration in culture by eliminating microglia
Vilalta, A., & Brown, G. C. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-58 · Cited by 58
Mathews Samuel, S., Satheesh, N. J., Ghosh, S., Büsselberg, D., Majeed, Y., Ding, H., & Triggle, C. R. (2019) · Cancers · doi:10.3390/cancers11111737 · Cited by 28
“Furthermore, intravenous administration of 2DG caused, although transient and not severe, effects similar to hypoglycemia, possibly because glucose is the primary fuel for brain and 2DG is a competitive inhibitor of glucose, inhibiting glycolysis [81].”
BackgroundAskar, M. A., Thabet, N. M., El-sayyad, G. S., El-Batal, A. I., kodous, M. A. E., Kawamura, G., Matsuda, A., Shawi, O. E. E., Helal, H., & Abdel-Rafei, M. K. (2021) · doi:10.21203/rs.3.rs-910507/v1 · Cited by 27
Metadata
- Authors
- Dwarakanath, B., Singh, D., Banerji, A., Sarin, R., Venkataramana, N., Jalali, R., Vishwanath, P., Mohanti, B., Tripathi, R., Kalia, V., & Jain, V.
- Venue
- Journal of Cancer Research and Therapeutics
- Publisher
- Medknow
- Published
- 2009
- Volume
- 5
- Issue
- 9
- Pages
- 21
- ISSN
- 0973-1482 (ISSN-L)
- OpenAlex
- W2021117623
- Cited by
- 194
- References
- 1
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.